Head-to-head comparison
Hers vs PauseRX
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
Women-focused telehealth brand from Hims and Hers offering compounded semaglutide on a 6-month plan.
From $199/mo (lowest dose rung) sema · $299/mo (brand-name) tirz · Verified July 2026
Marked down on: Limited public information on program details
FDAWarning letter issued to Hims & Hers Health, Inc. dba Hers in September 2025. See the FDA warning-letter database.
Desk Score
PauseRX is a nationwide compounded GLP-1 telehealth platform notable for its transparency: it names its 503A pharmacy partner (Strive Pharmacy in Gilbert, AZ), its physician network (Beluga Health).
$199/mo sema · From $249/mo (lowest dose rung) tirz · Verified July 2026
Marked down on: States served not listed — site claims nationwide, but you must contact support to confirm availability
Hers takes this head-to-head with the higher Desk Score, 76/100 (C) against 67/100 (C) for PauseRX. PauseRX still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
Hers
76/100
C
PauseRX
67/100
C
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | Hers | PauseRX |
|---|---|---|
| Semaglutide | From $199/molowest dose rung$199/mo (starting dose, compounded) | $199/mo$199/mo |
| Tirzepatide | $299/mobrand-name$299/mo (starting dose, plus a separate fee, brand-name) | From $249/molowest dose rung$249/mo (starting dose, compounded) |
| Coverage | All 50 states | Not listed on PauseRX's site (checked July 2026) |
| Brand-name | Yes | Yes |
| Oral option | Injectable only | Injectable only |
| Best for | Mainstream telehealth GLP-1 access. | Explicit 503A pharmacy and physician-network disclosure. |
| Desk Score | 76/100C | 67/100C |
The verdict
Desk pick — HersHers takes this head-to-head with the higher Desk Score, 76/100 (C) against 67/100 (C) for PauseRX. PauseRX still holds its ground where its strengths line up with yours.
Choose Hers if…
Mainstream telehealth GLP-1 access.
From $199/mo (lowest dose rung) sema · $299/mo (brand-name) tirz · All 50 states
FDAWarning letter issued to Hims & Hers Health, Inc. dba Hers in September 2025. See the FDA warning-letter database.
Choose PauseRX if…
Explicit 503A pharmacy and physician-network disclosure.
$199/mo sema · From $249/mo (lowest dose rung) tirz
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way. Read full breakdowns: Hers · PauseRX.
Also here
CoreAge Rx leads the whole ranking at 94/100
Whichever of these two you lean toward, our #1-rated provider outscores them both. One price at every dose, both molecules, all 50 states. The $99 and $149 figures are 12-month plans paid up front, not a monthly bill.
More head-to-heads
- CoreAge Rx vs Hers
- CoreAge Rx vs PauseRX
- Eden vs Hers
- Eden vs PauseRX
- Hers vs Pallas Health
- Pallas Health vs PauseRX
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.